DDrare: Database of Drug Development for Rare Diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
299	嚢胞性線維症	1

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04006873 (ClinicalTrials.gov)	September 3, 2019	2/7/2019	Gut Imaging for Function & Transit in Cystic Fibrosis Study 2	A Randomised Crossover Pilot Study of the Effects of Tezacaftor/Ivacaftor and Ivacaftor on Gastrointestinal Function Using Magnetic Resonance Imaging Parameters in People With Cystic Fibrosis	Cystic Fibrosis	Drug: Tezacaftor/Ivacaftor + Ivacaftor;Drug: Placebo oral tablet	Nottingham University Hospitals NHS Trust	Vertex Pharmaceuticals Incorporated;Cystic Fibrosis Foundation;Cystic Fibrosis Trust;University of Nottingham;Nottingham University Hospitals Charity	Active, not recruiting	12 Years	40 Years	All	12	Phase 2	United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT04006873
(ClinicalTrials.gov)

September 3, 2019

2/7/2019

Gut Imaging for Function & Transit in Cystic Fibrosis Study 2

A Randomised Crossover Pilot Study of the Effects of Tezacaftor/Ivacaftor and Ivacaftor on Gastrointestinal Function Using Magnetic Resonance Imaging Parameters in People With Cystic Fibrosis

Cystic Fibrosis

Drug: Tezacaftor/Ivacaftor + Ivacaftor;Drug: Placebo oral tablet

Nottingham University Hospitals NHS Trust

Vertex Pharmaceuticals Incorporated;Cystic Fibrosis Foundation;Cystic Fibrosis Trust;University of Nottingham;Nottingham University Hospitals Charity

Active, not recruiting

12 Years

40 Years

All

Phase 2

United Kingdom